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Incidence and risk factors for hepatitis C seroconversion in hemodial-
ysis: A prospective study. To delineate the incidence and risk factors for
seroconversion (SC) for HCV, from May 1991 to November 1992 we
followed all 401 patients (no i.v. drug abusers) dialyzed in 15 Belgian
hemodialysis (HD) units, none of which isolates anti-HCV (+) patients.
The sensitive ELISA II test was performed in the same laboratory for
all patients. ELISA II (+) sera were considered truly positive if specific
antibodies were detected by RIBA H against at least one HCV antigen.
Blood transfusions given from 12 months prior to inclusion in the study,
dialyzer reuse and frequency of dialysis monitor sterilization were
recorded. In May 1991, prevalence of truly positive ELISA 11 tests
averaged 13.5% (54/399). During the three consecutive six-month
periods, ELISA II became truly positive in 3 of 305 (1%), 4 of 314
(1.3%) and I of 313 (0.3%) patients, respectively, which was an average
yearly incidence of 1.7%. SC was preceded (I to 6 months) in all cases
by an unexplained, unprecedented increase in the alanine aminotrans-
ferase level. The mean monthly rate of transfusions was significantly
higher (P < 0.001) in eight patients with SC (0.7 0.6 U) than in 393
patients without SC (0.1 0.01 U). However, three of eight patients
with SC had not been transfused at all. SC was observed in only 3 of 13
units (1, 3 and 4 cases, respectively) dialyzing ELISA (+) patients. In
the unit with three SC, patients were always assigned a fixed station: SC
was observed only in patients dialyzed next to an ELISA 11 (+) patient(3 of 8 vs. 0 of 30, P < 0.02). These facts suggest nosocomial
transmission. SC was not associated with dialyzer reuse or the lack of
sterilization of the dialysis monitor after each session. In conclusion,
the yearly incidence of SC (ELISA II) averaged 1.7% in our group of
hemodialyzed patients. Contamination appeared to be both transfu.
sional and nosocomial. The absence of SC in 10 of 13 units dialyzing
ELISA (+) patients suggests that isolation of such patients is not yet
warranted. Strict adhesion to the "universal precautions" (CDC,
Atlanta) is probably sufficient to prevent nosocomial transmission.
Further long-term studies are needed to confirm these conclusions.
Infection by the hepatitis C virus (HCV) is frequent in
hemodialyzed patients [1—4], and worrysome as it often be-
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comes chronic and induces chronic liver disease [5, 6]. Its
prevention is therefore a major challenge for nephrologists.
We report on an 18-month prospective multicenter study
undertaken to assess the incidence [as expressed by the sero-
conversion (SC) rate] and the risk factors for HCV infection in
hemodialyzed patients.
Methods
Design of the study
A blood sample was obtained from all patients on chronic
hemodialysis (HD) in 15 Belgian units, every six months from
May 1991 to November 1992.
Hemodialyzed patients
In May 1991, 402 patients were included. They had been
dialyzed for Ito 257 (median 26) months. Their age ranged from
13 to 89 (median 61) years.
In November 1991 and May 1992 an additional 60 and 61
patients were included, respectively. Of these 121 patients, 117
had recently started HD, one resumed HD after a failed
transplantation and three had been transferred from other units.
Their age range was similar to that of the previously included
patients.
In November 1992, an additional 76 patients, recently started
on HD, were included. Their age range was similar to that of the
previously included patients. This last group completed the
assessment of the prevalence of HCV antibodies in patients
recently started on HD as well as of the prevalence of HCV
antibodies in the whole study group from May 1991 to Novem-
ber 1992.
Hemodialysis units
Fifteen collective HD units (hospital N = 14, low-care N = I)
participated in the study. None of these units isolated patients
with HCV antibodies. Patients on home HD were not included.
Serologic tests for HCV antibodies
All blood samples were tested by the Virology Laboratory of
the University Clinics St-Luc. Samples were centrifuged and
serum stored at —80°C until testing.
The sensitive second generation ELISA test for HCV [2, 7—9]
(Ortho HCV ELISA 2.0, further called ELISA II, Ortho
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Diagnostic Systems, Raritan, New Jersey, USA) was per-
formed on all serum samples, according to the manufacturer's
instructions. This test detects antibodies directed against both
non-structural (C200, a composite of C 100-3 and C33) and
structural (C22 = core) HCV antigens. A serum was considered
as ELISA-positive only if repeat testing proved positive.
All ELISA-positive sera were tested by second generation
Recombinant ImmunoBlot Assay [10, 11] (RIBA II, Ortho
Diagnostic Systems). In this test four HCV recombinant anti-
gens (Cl00-3, 5-1-1, C33, C22) and superoxide dismutase were
blotted as separate bands on a nitrocellulose strip. After incu-
bation with the patient's serum, the presence of specific anti-
bodies was revealed by a goat antihuman IgG antibody conju-
gated with a peroxidase.
In this study the ELISA II test was taken as truly positive if
specific antibodies were detected against at least one HCV
antigen by the RIBA II test. Indeed, in most HD patients with
such a RIBA II pattern, HCV-RNA can be demonstrated in
serum by the polymerase chain reaction [12]. The few ELISA II
(+) patients with a non-reactive RIBA II were excluded from
the calculations of incidence and prevalence.
Risk factors for SC for HCV
Blood transfusions were recorded for each patient. As infec-
tion may precede SC by up to 12 months [9], the listing included
transfusions given from 12 months prior to inclusion up to the
end of the study.
All blood derivatives able to transmit viral infections (red
cells, whole blood, plasma, platelets) were recorded. Pasteur-
ized albumin solutions were excluded [13].
The existence of a history of intravenous drug abuse (IVDA)
and the presence of antibodies against human immunodefi-
ciency virus (HIV) were specifically checked by a questionnaire
to the referring nephrologists.
Dialyzer reuse and the frequency of dialysis monitor steril-
ization were recorded.
Sexual partners of patients who seroconverted were tested by
ELISA II.
Statistics
Results are expressed as mean SEM as indicated. Unpaired
Student's t-test, and Fisher's exact test were used as
indicated. P values <0.05 were considered as significant.
Results
Prevalence of ELISA positive patients at the time of inclusion
The ELISA II test was initially positive in 57 of 402, 3 of 60,
3 of 61 and 6 of 76 patients included in May 1991, November
1991, May 1992 and November 1992, respectively. The pres-
ence of specific anti-HCV antibodies was detected by RIBA II
in 54 of 57, 1 of 3, 3 of 3 and 6 of 6 cases, respectively (Table I).
In May 1991, the prevalence of truly positive ELISA II patients
ranged from 0 to 31% in the 15 participating units.
Adequacy of serologic follow-up
Out of 523 patients included in May 1991, November 1991
and May 1992, 158 did not complete the study as a result of
death (N = 93), renal transplantation (N = 50), transfer to other
dialysis units (N = 11), recovery of renal function (N = 3), or
Table 1. Prevalence and incidence of truly positive ELISA II tests
May
1991
November
1991
May
1992
November
1992
Prevalence in new — 1.7% 5% 8%
patients (1/60) (3/6 1) (6/76)
Prevalence in the whole 13.4% 12.4% 12.2% 11.8%
group (54/399) (51/410) (51/419) (51/433)
Incidence/6 months — 1%
(3/305)
1.3%
(4/314)
0.3%
(1/313)
Note that ELISA II (+) tests non-reactive by RIBA II were excluded
from the calculations.
transfer to peritoneal dialysis (N = 1). Of the total of 1679
expected serum samples, only six (0.36%) were missing, all in
seronegative patients who remained so at later follow-up.
Incidence of SC for HCV
During the three consecutive six-month periods, three, five
and one patient, respectively, became ELISA (+). In eight
patients specific reactivity was detected by RIBA II against
HCV antigen(s) including C33 in seven of eight cases. In the
ninth patient, suffering from multiple myeloma, the RIBA II test
(May 1992) was non-reactive; the false positive ELISA was
ascribed to the paraprotein [14]. The six month incidence of
true SC was thus 3 of 305 (1%), 4 of 314 (1.3%) and 1 of 313
(0.3%), respectively, which is an average of 1.7% per year. We
further calculated the SC rate in all (N = 193) patients already
on HD for six months in May 1991 and followed throughout the
18 month study; five SC were observed for an average yearly
incidence of 1.73%, thus identical to that observed in the whole
group.
Alanine aminotransferase (ALT) level in patients who
seroconverted
ALT determinations obtained every one to two months from
the onset of HD were reviewed in the eight patients with true
SC, In each case, SC was preceded (1 to 6 months) by an
unexplained, sustained elevation of the ALT level (>6 weeks
duration, at least 2—mean: 5—ALT results above the upper
limit of normal values). This rise was not accounted for by
hepatitis B virus infection or hepatotoxic drugs, and was noted
for the first time since the initiation of HD.
Risk factors for SC for HCV
The mean monthly rate of blood transfusions was signifi-
cantly (P < 0.001, unpaired t-test) higher in the eight patients
with SC (0.7 0.6 unit) than in patients without SC (0.1 0.01
unit).
It is noteworthy that two patients exclusively received
ELISA I negative blood units whereas three patients had not
been transfused at all after May 1, 1990.
SC were observed in only three of the 15 participating units
(1, 3 and 4 cases, respectively). In May 1991 these three units
treated 34% of the patients. Initial prevalence of truly positive
ELISA II patients averaged 16.3% (22 of 135), a value similar to
the 12.6% (32 of 253) observed in the 10 other units with ELISA
(+) patients. The proportion of ELISA II (+) patients in whom
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Table 2. Risk factors for seroconversion (SC) for HCV
SC
(N = 8)
NoSC(N = 393)
P
value
Transfusions
Mean number SEM of units/month 0.7 0.6 0.1 0.01 <0.001
Number of patients not transfused 3/8 180/393 NS
Number of patients transfused with 2/8 NA
ELISA I negative units only
i.v. Drug abuse (number of patients) 0 0
Dialyzer reuse (number of treated 3/8 158/393 NS
patients)
Sterilization of dialysis monitor after 3/8 88/393 NS
each session (number of treated
patients)
Abbreviations are: NS, not significant; NA, not available.
RIBA II detected antibodies against 2 HCV antigens was
similar in the three units with (18 of 22) and in the 10 units
without (27 of 32) Sc.
In the unit with three SC, patients (N = 38) were always
assigned the same station. The prevalence of SC was signifi-
cantly higher (3 of 8) among patients dialyzed next to an ELISA
II positive patient than among the others (0 of 30; P < 0.02,
Fisher's exact test).
No patient included in the study was an i.v. drug abuser or
had antibodies against HIV.
Incidence of SC was not associated with dialyzer reuse or
lack of sterilization of dialysis monitor after each session (Table
2).
We tested the sexual partners of four patients with SC.
ELISA II proved negative in all. No partner was identified in
three widowed patients, whereas one partner was lost to
follow-up.
Serologic follow-up of ELISA positive patients
All truly positive ELISA II patients (N = 56) remained
ELISA II (+) throughout follow-up (68 patient-years).
Evolution ofthe prevalence of truly positive ELISA tests over
the study period
Over the 18 months' study period, the overall prevalence of
truly positive ELISA II tests decreased slightly from 54 of 399
(13.4%) in May 1991 to 51 of 410(12.4%) in November 1991, 51
of 419 (12.2%) in May 1992 and 51 of 433 (11.8%) in November
1992 (Table 1).
Discussion
Our study defined prospectively the SC rate for HCV with the
sensitive ELISA II in a large series of 401 HD patients. The SC
rate averages 1.7% per year. The recent infection by HCV of
the patients with SC is confirmed by a recent, unprecedented,
ALT level increase in each patient and a RIBA II pattern with
predominant anti-C33 antibodies compatible with recent SC
[15].
Previous data on this subject were limited to a large retro-
spective study and three small prospective studies. Dentico et
al [16] using a less sensitive ELISA I test reported in 115 Italian
HD patients, a yearly incidence of SC for HCV falling from 6.1
to 2.2% between 1984 and 1990. Unfortunately, this retrospec-
tive study relied on frozen sera available in only less than half
the population at risk. In the absence of information on the
reason why sera were available for some patients and not for
others, these results are open to question. Two small prospec-
tive studies relying on the ELISA I test in 35 and 48 HD patients
followed for 12 months, reported a yearly incidence of 11.4%
(Saudi Arabia) [61 and 6% (France) [17], respectively. These
figures are probably underestimates of the actual incidence in
these populations as the sensitivity of the ELISA I test is only
54 to 76% of that of the ELISA II test in HD patients [2, 7, 8,
18]. More recently, a prospective study relying on the second
generation assay reported a yearly incidence of 4.9% in 39 HD
patients followed in Hong Kong for 19 months [18].
Our study confirms that blood transfusions are a risk factor
for the transmission of HCV in HD [1, 3,4]. The small decrease
in the prevalence of truly positive ELISA II patients observed
in our series probably reflects the reduction in transfusion
requirements due to the introduction of erythropoietin treat-
ment in Belgium by mid-1989 as well as the screening of blood
units initiated in Belgium with ELISA I in May 1990 and with
ELISA II in August 1991.
However, factors other than transfusion contribute to the
transmission of HCV as demonstrated by the absence of blood
transfusions in three of the eight patients with SC. Neither
sexual transmission nor IVDA can be incriminated—indeed,
the four sexual partners tested were ELISA II negative (includ-
ing the partners of 2 nontransfused patients with SC) and no
patient was an IVDA. Interestingly, other studies have detected
HCV antibodies in up to 19 to 39% of HD patients never given
a blood transfusion [4, 19, 20].
These facts taken together with the clustering of SC in three
units point to the possibility of a nosocomial transmission. This
hypothesis is supported by our observation that patients dia-
lyzed in a bed adjacent to that of an ELISA (+) patient had a
significantly higher risk of SC than the others in the same unit.
To prevent nosocomial transmission, several groups have
advocated the segregation of HCV(+) from HCV(—) patients
[4, 20, 21]. This recommendation is questionable as its effec-
tiveness is unknown and its implementation difficult.
Effectiveness is limited by the up to one year delay between
HCV infection and the detection of antibodies by the ELISA II
test [9]. Admittedly, new tests [5, 22] will probably decrease
this delay and improve the detection of HCV infection. Fur-
thermore, the possibility of a lack of cross immunity between
different strains of HCV must be borne in mind. Indeed, unlike
the hepatitis B virus, the HCV exhibits a major genomic
variability [23] and it has recently been demonstrated that
sequential inoculation of convalescent chimpanzees with differ-
ent HCV strains results in the reappearance of viremia due to
infection with the last inoculated strain [24]. This concern has
led some transplantation units to refuse to transplant ELISA +
organs in ELISA + recipients [251. Grouping of ELISA ÷
patients in dialysis units might thus increase their risk of
acquiring multiple HCV strains.
Implementation of a rigorous separation between patients
according to their HCV status is rather cumbersome. In units
also treating HBsAg positive patients, this would imply up to
four separate facilities (B+C+, B+C—, B—C+ and B—C—)!
The German Association of Clinical Nephrologists has re-
cently recommended isolating only ELISA II (+) patients with
ALT levels higher than the double of the upper limit of normal
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[26]. This proposal fails to consider that many HD patients have
normal ALT values despite the fact that they are infective as
demonstrated by a positive polymerase chain reaction for
HCV-RNA [18].
Our observations suggest that isolation of ELISA + patients
is not mandatory to prevent nosocomial HCV transmission in
HD units. Indeed no SC for HCV was observed over 18 months
in 10 of 13 units dialyzing ELISA (+) together with ELISA (—)
patients. As the highest prevalence among participating units
was 31%, our data do not permit definition of the risk of
nosocomial HCV infection in units with an even higher preva-
lence. Interestingly however, no SC was observed throughout
the study in the unit with a 31% prevalence. The lack of
seroconversion in 10 units is not accounted for by a lower
prevalence of ELISA II positive patients. A lower infectivity of
ELISA (+) patients in these 10 units appears equally unlikely as
the RIBA II pattern [10, 11] was similar in units without and
with SC. Similarly, there was no difference in dialyzer reuse or
frequency of dialysis monitor sterilization between units with-
out and with contamination. The most likely remaining expla-
nation to be considered is that measures to prevent cross-
contamination were better observed in the units without than in
units with SCs. Such measures are detailed in the "universal
precautions for prevention of transmission of blood borne
pathogens in health care settings" [27] and "recommended
precautions for patients undergoing hemodialysis who have
AIDS or non-A non-B hepatitis" [28] delineated by the Center
for Disease Control (Atlanta, Georgia, USA). They include
cleaning and disinfection of instruments, machines and environ-
mental surfaces that are routinely touched, avoidance of shar-
ing of articles between patients, frequent handwashing and use
of gloves! A recent outbreak of HCV infection in a HD unit was
effectively controlled by the implementation of these simple,
too often neglected measures [29].
In conclusion, the yearly incidence of SC for HCV (ELISA
II) averages 1.7% in our prospective study in HD patients.
Contamination appears to be both transfusional and nosoco-
mial. The absence of SC in most units dialyzing ELISA +
patients suggests that isolation of such patients is not yet
warranted. By contrast, strict adhesion to the "CDC guide-
lines" is recommended. Further long-term studies are needed
to confirm these conclusions.
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